CSI Market
Sign In | Register

Actinium Pharmaceuticals Inc (ATNM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ATNM Annual Cash Flow →
Tracking cash flow results across Actinium Pharmaceuticals Inc to Dec 31 2024 helps illustrate how Jun 30 2026's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Dec 31 2024)
Operating Activities
Income22.38
Depreciation & amortization0.46
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.13
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase In Legal Fees Payable-
Gain Loss On Disposition Of Property-
Increase Decrease In Longterm License Revenues Deferred-
Increase Decrease In Operating Lease Rightofuse Assets-
Increase Decrease In Operating Lease Liability-0.42
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable, Related Parties0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities1.21
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.12
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-35.12
Discontinued operations0.00
Net Cash flow from Operating Activities-11.05
Investing Activities
Capital Expenditures-0.48
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Acquire Security Deposit-
Increase in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Finance Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.48
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.01
Proceeds From Exercise Of Options And Warrants For Cash-
Proceeds From Options Exercises-
Finance Lease Principal Payments-0.01
Proceeds From Issuance Of Common Stock And Warrant Net-
Sales Of Shares Of Common Stock Net Of Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-11.53
Total Cash Flow-11.52
4 historic quarters locked

Sign in to unlock the full Actinium Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Actinium Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-086769

Figures are derived from filed reports and may be restated. Historical data is subject to revision.